Literature DB >> 22548391

Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy.

Zahra Hallaji1, Maryam Ghiasi, Ayat Eisazadeh, Maede Rayati Damavandi.   

Abstract

BACKGROUND/
PURPOSE: Narrowband ultraviolet B (NB-UVB) has been accepted as an effective therapy for generalized vitiligo. On the other hand, different factors seem to contribute to a good response. The purpose of this study is to evaluate the influence of disease duration on its clinical response to NB-UVB phototherapy.
METHODS: In this open and uncontrolled study, vitiligo was considered 'recent' when the duration of disease was less than or equal to 4 years and 'long standing' when it was greater than 4 years. The patients received NB-UVB thrice weekly with an initial dose of 200 mJ/cm(2) and 10% increments at each subsequent treatment. After categorizing the clinical response to four groups (mild, moderate, good, and excellent), duration of disease and clinical response to NB-UVB were correlated statistically using the t-test.
RESULTS: There were 63 patients: 34 women and 29 men, aged 6-60 years. The mean of disease duration was 10.13 ± 9.1 years. Vitiligo was 'recent' in 26 and 'long standing' in 37 patients. The mean of overall response was 51.94 ± 18.48%. Higher grades of response were more prevalent in patients with recent vitiligo than those with long-standing disease, and there was also statistically significant difference in overall response between these two groups of disease duration (P = 0.023).
CONCLUSION: The early treatment of generalized vitiligo may enhance the chance of successful repigmentation.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22548391     DOI: 10.1111/j.1600-0781.2012.00648.x

Source DB:  PubMed          Journal:  Photodermatol Photoimmunol Photomed        ISSN: 0905-4383            Impact factor:   3.135


  6 in total

1.  A comparative study of combined treatment with fractional carbon dioxide and targeted ultraviolet B phototherapy for facial vitiligo.

Authors:  Silada Kanokrungsee; Kumutnart Chanprapaph; Chayada Chaiyabutr; Vasanop Vachiramon
Journal:  Lasers Med Sci       Date:  2016-06-13       Impact factor: 3.161

2.  Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT.

Authors:  Jonathan M Batchelor; Kim S Thomas; Perways Akram; Jaskiran Azad; Anthony Bewley; Joanne R Chalmers; Seau Tak Cheung; Lelia Duley; Viktoria Eleftheriadou; Robert Ellis; Adam Ferguson; Jonathan Mr Goulding; Rachel H Haines; Hamdi Hamad; John R Ingram; Bisola Laguda; Paul Leighton; Nick Levell; Areti Makrygeorgou; Garry D Meakin; Adam Millington; Malobi Ogboli; Amirtha Rajasekaran; Jane C Ravenscroft; Andrew Rogers; Tracey H Sach; Miriam Santer; Julia Stainforth; Wei Tan; Shyamal Wahie; Jennifer White; Maxine E Whitton; Hywel C Williams; Andrew Wright; Alan A Montgomery
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

3.  Feasibility, double-blind, randomised, placebo-controlled, multi-centre trial of hand-held NB-UVB phototherapy for the treatment of vitiligo at home (HI-Light trial: Home Intervention of Light therapy).

Authors:  Viktoria Eleftheriadou; Kim Thomas; Jane Ravenscroft; Maxine Whitton; Jonathan Batchelor; Hywel Williams
Journal:  Trials       Date:  2014-02-08       Impact factor: 2.279

4.  Leucine-rich glioma inactivated 3: a novel keratinocyte-derived melanogenic cytokine in vitiligo patients.

Authors:  Azza Gaber Antar Farag; Mostafa Ahmed Hammam; Dalia Rifaat Al-Sharaky; Ghada Mohamed El-Boghdady
Journal:  An Bras Dermatol       Date:  2019-10-17       Impact factor: 1.896

5.  Association of IFN-γ : IL-10 Cytokine Ratio with Nonsegmental Vitiligo Pathogenesis.

Authors:  Yaswanth Ala; Mohammed Khalid Pasha; Raja Narasimha Rao; Prasanna Latha Komaravalli; Parveen Jahan
Journal:  Autoimmune Dis       Date:  2015-09-09

6.  Home interventions and light therapy for the treatment of vitiligo (HI-Light Vitiligo Trial): study protocol for a randomised controlled trial.

Authors:  Rachel H Haines; Kim S Thomas; Alan A Montgomery; Jane C Ravenscroft; Perways Akram; Joanne R Chalmers; Diane Whitham; Lelia Duley; Viktoria Eleftheriadou; Garry Meakin; Eleanor J Mitchell; Jennifer White; Andy Rogers; Tracey Sach; Miriam Santer; Wei Tan; Trish Hepburn; Hywel C Williams; Jonathan Batchelor
Journal:  BMJ Open       Date:  2018-04-03       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.